med-20260717 0000910329 FALSE 0000910329 2026-07-17 2026-07-17 0000910329 exch:XNYS 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 (I.R.S. Employer Identification No.) 1501 S. Clinton Street, Suite 500 , Baltimore , Maryland 21224 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: ( 410 ) 581-8042 N/A (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share MED New York Stock Exchange Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 7.01.    Regulation FD Disclosure. On July 17, 2026 Medifast, Inc. issued a Press Release announcing the rebranding of OPTAVIA, the lifestyle brand and a wholly-owned subsidiary of the company, to Trilivy, a comprehensive metabolic health system. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01.    Financial Statements and Exhibits. (d) Exhibits. 99.1 Medifast Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL Document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEDIFAST, INC. By: /s/ James P. Maloney James P. Maloney Chief Financial Officer Dated: July 17, 2026

Medifast, Inc. announced on July 17, 2026, that its wholly-owned subsidiary OPTAVIA is being rebranded to Trilivy to operate as a comprehensive metabolic health system. This strategic rebranding aims to better align the brand with its health and wellness mission and reflects an evolution in the company's market approach.

On July 17, 2026, Medifast, Inc. announced the rebranding of its wholly-owned subsidiary OPTAVIA to Trilivy, which will operate as a comprehensive metabolic health system. This strategic change is intended to better align the brand with its mission of promoting health and wellness through metabolic health solutions. The rebranding reflects an evolution in the company’s approach to addressing customer needs in the health and wellness market. The announcement is documented in a press release attached as Exhibit 99.1 and is considered important for investors and stakeholders aware of the company's branding strategy.

Medifast, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means